HS-20137 vs SHR-1139

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 p19 · full Psoriasis pipeline

HS-20137

Developed by Qyuns Therapeutics and partners

Phase 3 in Psoriasismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT07879885 (registry estimate)

No aligned efficacy figure on record for this race.

SHR-1139

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 2 in Psoriasismonoclonal antibody (dual IL-23p19/IL-36R)
Weak signal

NCT07051538 · Phase 1 · completed

This early-phase study randomized 64 participants to SHR-1139 or placebo under full blinding, but it was designed to check safety and tolerability, not to test whether the drug improves psoriasis, and no results have been posted, so no conclusion about benefit can yet be drawn from it. Its registered primary outcome on ClinicalTrials.gov is "Adverse events (AEs)" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07719530 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHS-20137SHR-1139
PASI 75—Trial running · NCT06844799—Not reported
PASI 90—Trial running · NCT06844799—Not reported
PASI 100—Trial running · NCT06844799—Not reported
sPGA 0/1—Trial running · NCT06844799—Not reported
DLQI, change—Trial running · NCT06844799—Not reported

PASI 75

HS-20137
—Trial running · NCT06844799
SHR-1139
—Not reported

PASI 90

HS-20137
—Trial running · NCT06844799
SHR-1139
—Not reported

PASI 100

HS-20137
—Trial running · NCT06844799
SHR-1139
—Not reported

sPGA 0/1

HS-20137
—Trial running · NCT06844799
SHR-1139
—Not reported

DLQI, change

HS-20137
—Trial running · NCT06844799
SHR-1139
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HS-20137: no structured comparison results are available for Psoriasis.

SHR-1139: no structured comparison results are available for Psoriasis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS-20137's landscape · SHR-1139's landscape